Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years

被引：292

作者：

Romanowski, B. ^{[1
]}

de Borba, P. Colares ^{[2
]}

Naud, P. S. ^{[3
]}

Roteli-Martins, C. M. ^{[4
]}

De Carvalho, N. S. ^{[5
,6
]}

Teixeira, J. C. ^{[7
]}

Aoki, F. ^{[8
]}

Ramjattan, B. ^{[9
]}

Shier, R. M. ^{[10
]}

Somani, R. ^{[11
]}

Barbier, S. ^{[12
]}

Blatter, M. M. ^{[13
]}

Chambers, C. ^{[14
]}

Ferris, D. ^{[15
]}

Gall, S. A. ^{[16
]}

Guerra, F. A. ^{[17
]}

Harper, D. M. ^{[18
]}

Hedrick, J. A. ^{[19
]}

Henry, D. C. ^{[20
]}

Korn, A. P. ^{[21
]}

Kroll, R. ^{[22
]}

Moscicki, A-B ^{[23
]}

Rosenfeld, W. D. ^{[24
]}

Sullivan, B. J. ^{[25
]}

Thoming, C. S. ^{[26
]}

Tyring, S. K. ^{[27
]}

Wheeler, C. M. ^{[28
]}

Dubin, G. ^{[29
]}

Schuind, A. ^{[29
]}

Zahaf, T. ^{[30
]}

机构：

[1] Univ Alberta, Edmonton, AB T6G 2C8, Canada

[2] Ceara Canc Prevent Inst, Fortaleza, Ceara, Brazil

[3] Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil

[4] Leonor Mendes de Barros Hosp, Hlth State Dept, Sao Paulo, Brazil

[5] Univ Fed Parana, Dept Obstet & Gynaecol, BR-80060000 Curitiba, Parana, Brazil

[6] Clin Hosp, Obstetr Gynecol & Infect Dis Sector, Curitiba, Parana, Brazil

[7] Univ Estadual Campinas, CAISM, Dept Gynaecol, Div Oncol, Campinas, SP, Brazil

[8] Univ Manitoba, Winnipeg, MB, Canada

[9] Cowan Ave Med Clin, St John, NF, Canada

[10] Univ Toronto, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada

[11] Glover Med Clin, Langley, BC, Canada

[12] Womens Clin Res Ctr, Seattle, WA USA

[13] Primary Phys Res, Pittsburgh, PA USA

[14] Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA

[15] Med Coll Georgia, Augusta, GA 30912 USA

[16] Univ Louisville, Sch Med, Louisville, KY 40292 USA

[17] San Antonio Metropolitan Hlth Dist, San Antonio, TX USA

[18] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Hanover, NH 03756 USA

[19] Kentucky Pediat & Adult Res, Bardstow, KY USA

[20] J Lewis Res, Salt Lake City, UT USA

[21] San Francisco Gen Hosp, San Francisco, CA 94110 USA

[22] Womens Clin Res Ctr, Seattle, WA USA

[23] Univ Calif San Francisco, San Francisco, CA 94143 USA

[24] Goryeb Childrens Hosp, Atlantic Hlth, Dept Pediat, Morristown, NJ USA

[25] Marshfield Clin Fdn Med Res & Educ, Marshfield, WI 54449 USA

[26] Westover Hts Clin, Portland, OR USA

[27] Univ Texas Hlth Sci Ctr Houston, Houston, TX USA

[28] Univ New Mexico, Hlth Sci Ctr, Albuquerque, NM 87131 USA

[29] GSK Biol, King Of Prussia, PA USA

[30] GSK Biol, Rixensart, Belgium

来源：

LANCET | 2009年 / 374卷 / 9706期

关键词：

SUBSEQUENT HPV INFECTION; PARTICLE VACCINE; CERVICAL-CANCER; YOUNG-WOMEN; NATURAL-HISTORY; ANTIBODY-LEVELS; DOUBLE-BLIND; HEPATITIS-B; TYPE-16; RISK;

D O I：

10.1016/S0140-6736(09)61567-1

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background Prophylactic human papillomavirus (HPV) vaccines have to provide sustained protection. We assessed efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine up to 6.4 years. Methods Women aged 15-25 years, with normal cervical cytology, who were HPV-16/18 seronegative and oncogenic HPV DNA-negative (14 types) at screening participated in a double-blind, randomised, placebo-controlled initial study (n=1113; 560 vaccine group vs 553 placebo group) and follow-up study (n=776; 393 vs 383). 27 sites in three countries participated in the follow-up study. Cervical samples were tested every 6 months for HPV DNA. Management of abnormal cytologies was prespecified, and HPV-16/18 antibody titres were assessed. The primary objective was to assess long-term vaccine efficacy in the prevention of incident cervical infection with HPV 16 or HPV 18, or both. We report the analyses up to 6.4 years of this follow-up study and combined with the initial study. For the primary endpoint, the efficacy analysis was done in the according-to-protocol (ATP) cohort; the analysis of cervical intraepithelial neoplasia grade 2 and above (CIN2+) was done in the total vaccinated cohort (TVC). The study is registered with ClinicalTrials.gov, number NCT00120848. Findings For the combined analysis of the initial and follow-up studies, the ATP efficacy cohort included 465 women in the vaccine group and 454 in the placebo group; the TVC included 560 women in the vaccine group and 553 in the placebo group. Vaccine efficacy against incident infection with HPV 16/18 was 95.3% (95% C1 87.4-98.7) and against 12-month persistent infection was 100% (81.8-100). Vaccine efficacy against CIN2+ was 100% (51.3-100) for lesions associated with HPV-16/18 and 71.9% (20.6-91.9) for lesions independent of HPV DNA. Antibody concentrations by ELISA remained 12-fold or more higher than after natural infection (both antigens). Safety outcomes were similar between groups: during the follow-up study, 30 (8%) participants reported a serious adverse event in the vaccine group versus 37 (10%) in the placebo group. None was judged related or possibly related to vaccination, and no deaths occurred. Interpretation Our findings show excellent long-term efficacy, high and sustained immunogenicity and favourable safety of the HPV-16/18 AS04-adjuvanted vaccine up to 6.4 years.

引用

页码：1975 / 1985

页数：11

共 50 条

[31] Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study [J].

Wheeler, Cosette M. ;

Skinner, S. Rachel ;

Rowena Del Rosario-Raymundo, M. ;

Garland, Suzanne M. ;

Chatterjee, Archana ;

Lazcano-Ponce, Eduardo ;

Salmeron, Jorge ;

McNeil, Shelly ;

Stapleton, Jack T. ;

Bouchard, Celine ;

Martens, Mark G. ;

Money, Deborah M. ;

Quek, Swee Chong ;

Romanowski, Barbara ;

Vallejos, Carlos S. ;

ter Harmsel, Bram ;

Prilepskaya, Vera ;

Fong, Kah Leng ;

Kitchener, Henry ;

Minkina, Galina ;

Lim, Yong Kuei Timothy ;

Stoney, Tanya ;

Chakhtoura, Nahida ;

Cruickshank, Margaret E. ;

Savicheva, Alevtina ;

da Silva, Daniel Pereira ;

Ferguson, Murdo ;

Molijn, Anco C. ;

Quint, Wim G. V. ;

Hardt, Karin ;

Descamps, Dominique ;

Suryakiran, Pemmaraju V. ;

Karkada, Naveen ;

Geeraerts, Brecht ;

Dubin, Gary ;

Struyf, Frank .

LANCET INFECTIOUS DISEASES, 2016, 16 (10) :1154-1168

[32] Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial [J].

Einstein, Mark H. ;

Takacs, Peter ;

Chatterjee, Archana ;

Sperling, Rhoda S. ;

Chakhtoura, Nahida ;

Blatter, Mark M. ;

Lalezari, Jacob ;

David, Marie-Pierre ;

Lin, Lan ;

Struyf, Frank ;

Dubin, Gary .

HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (12) :3435-3445

[33] Efficacy of the AS04-adjuvanted HPV-16/18 vaccine in young Chinese women with oncogenic HPV infection at baseline: post-hoc analysis of a randomized controlled trial [J].

Hu, Shangying ;

Xu, Xiaoqian ;

Zhu, Fengcai ;

Hong, Ying ;

Hu, Yuemei ;

Zhang, Xun ;

Pan, Qinjing ;

Zhang, Wenhua ;

Zhang, Chengfu ;

Yang, Xiaoping ;

Yu, Jiaxi ;

Zhu, Jiahong ;

Zhu, Yejiang ;

Chen, Feng ;

Zhao, Shuang ;

Karkada, Naveen ;

Tang, Haiwen ;

Bi, Dan ;

Struyf, Frank ;

Zhao, Fanghui .

HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (04) :955-964

[34] Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women Open follow-up of a randomized clinical trial up to 4 years post-vaccination [J].

Konno, Ryo ;

Yoshikawa, Hiroyuki ;

Okutani, Marie ;

Quint, Wim ;

Suryakiran, Pemmaraju V. ;

Lin, Lan ;

Struyf, Frank .

HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (07) :1781-1794

[35] Efficacy of AS04-Adjuvanted Vaccine Against Human Papillomavirus (HPV) Types 16 and 18 in Clearing Incident HPV Infections: Pooled Analysis of Data From the Costa Rica Vaccine Trial and the PATRICIA Study [J].

Tota, Joseph E. ;

Struyf, Frank ;

Hildesheim, Allan ;

Gonzalez, Paula ;

Ryser, Martin ;

Herrero, Rolando ;

Schussler, John ;

Karkada, Naveen ;

Rodriguez, Ana Cecilia ;

Folschweiller, Nicolas ;

Porras, Carolina ;

Schiffman, Mark ;

Schiller, John T. ;

Quint, Wim ;

Kreimer, Aimee R. ;

Lehtinen, Matti ;

Wheeler, Cosette M. ;

Sampson, Joshua N. .

JOURNAL OF INFECTIOUS DISEASES, 2021, 223 (09) :1576-1581

[36] Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada [J].

Michele Kohli ;

Donna Lawrence ;

Jennifer Haig ;

Andrea Anonychuk ;

Nadia Demarteau .

BMC Public Health, 12

[37] AS04-adjuvanted human papillomavirus types 16/18 vaccine (Cervarix®): A guide to its use [J].

Lyseng-Williamson K.A. ;

McKeage K. .

Drugs & Therapy Perspectives, 2012, 28 (3) :1-6

[38] Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: Follow-up through Month 48 in a Phase III randomized study [J].

Einstein, Mark H. ;

Levin, Myron J. ;

Chatterjee, Archana ;

Chakhtoura, Nahida ;

Takacs, Peter ;

Catteau, Gregory ;

Dessy, Francis J. ;

Moris, Philippe ;

Lin, Lan ;

Struyf, Frank ;

Dubin, Gary .

HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (12) :3455-3465

[39] Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9-14 years: Results to month 36 from a randomized trial [J].

Leung, Ting Fan ;

Liu, Anthony Pak-Yin ;

Lim, Fong Seng ;

Thollot, Franck ;

Oh, Helen May Lin ;

Lee, Bee Wah ;

Rombo, Lars ;

Tan, Ngiap Chuan ;

Rouzier, Roman ;

De Simoni, Stephanie ;

Suryakiran, Pemmaraju ;

Hezareh, Marjan ;

Thomas, Florence ;

Folschweiller, Nicolas ;

Struyf, Frank .

VACCINE, 2018, 36 (01) :98-106

[40] 2-Dose Schedule of AS04-Adjuvanted Human Papillomavirus Types 16/18 Vaccine Reply [J].

Stevenson, Louise ;

Huang, L. -M. ;

Berlaimont, Valerie ;

Folschweiller, Nicolas .

JOURNAL OF INFECTIOUS DISEASES, 2017, 216 (06) :783-785

← 1 2 3 4 5 →